As of November 6, 2026, Prelude Therapeutics Inc is a publicly traded company (Nasdaq: PRLD). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 16%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Krishna Vaddi, the chief executive and a director (13.15%, reporting on Schedule 13G) (Schedule 13D/A, April 23, 2026).
Is this your company?
About to sign with, pay or invest in Prelude Therapeutics Inc? See the free Snapshot first.
Free to see. No signup.
Is Prelude Therapeutics Inc a real, registered company?
- Prelude Therapeutics Inc files with the SEC under CIK 1678660 (its SEC filings).
- Its shares are listed under the ticker PRLD on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Wilmington, Delaware, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Prelude Therapeutics Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Charles Q. Morris, Chief Medical Officer (Form 8-K filed 2026-04-15). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Soleus Capital Management, L.P. (filed 2026-07-08).
Who are Prelude Therapeutics Inc's owners and officers?
Prelude Therapeutics Inc: incorporated in Delaware; business address in Wilmington, Delaware; industry Pharmaceutical Preparations (Schedule 13G, 2026-07-08).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-07-08 | Soleus Capital Management, L.P. | 5.2% |
| Schedule 13G, 2026-04-28 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13D/A, 2026-04-23 | Orbimed Advisors LLC | 16% |
| Schedule 13D/A, 2026-04-22 | Baker Bros. Advisors LP | 15.5% |
| Schedule 13G/A, 2026-02-13 | Vaddi Krishna | 13.15% |
| Schedule 13G, 2025-11-07 | Incyte Corp | 9.9% |
Questions about who owns Prelude Therapeutics Inc
Who owns Prelude Therapeutics Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Prelude Therapeutics Inc: Orbimed Advisors LLC (16%, Schedule 13D/A, filed 2026-04-23), Baker Bros. Advisors LP (15.5%, Schedule 13D/A, filed 2026-04-22), Vaddi Krishna (13.15%, Schedule 13G/A, filed 2026-02-13), Ra Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-04-28) and Incyte Corp (9.9%, Schedule 13G, filed 2025-11-07); 1 more is listed above.
Who are the largest shareholders of Prelude Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Prelude Therapeutics Inc on this page are Orbimed Advisors LLC (16%), Baker Bros. Advisors LP (15.5%) and Vaddi Krishna (13.15%).
When did Orbimed Advisors LLC buy into Prelude Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-04-23, reporting 16%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Prelude Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Prelude Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Prelude Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-15 | Charles Q. Morris | Chief Medical Officer | appointed | 2026-04-20 |
Which insiders own Prelude Therapeutics Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 6,475,882 shares (8.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-28).
- , a 10% owner: 6,475,882 shares (8.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-28).
- RA Capital Healthcare Fund LP, a 10% owner: 6,475,882 shares (8.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-28).
- RA Capital, a 10% owner: 6,475,882 shares (8.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-28).
- , the chief executive and a director: 2,693,625 shares (3.4% of shares outstanding), 1,999,296 held directly and 694,329 indirectly (Form 4, 2025-03-27).
Shares outstanding: 79,803,485 as of 2026-08-06, from the company's latest SEC cover page.
How much has Prelude Therapeutics Inc raised?
No fundraising or offering filing from Prelude Therapeutics Inc is on file with us.
Keep reading
More on Prelude Therapeutics Inc and the records around it.
Prelude Therapeutics Inc elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes Apr 2026
Companies that share a holder
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: CALCIMEDICA, INC. (May 2026), Aprea Therapeutics, Inc. (Apr 2026), INVIVYD, INC. (Feb 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/prelude-therapeutics